BD simplifies at-home HPV testing with new self-collection solution

FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE:BDX), a prominent healthcare equipment player with annual revenues of $21.4 billion and strong financial health according to InvestingPro, announced Wednesday a new self-collection solution for HPV testing in markets outside the United States that aims to expand access to cervical cancer screening.

The technology, which has received certification through the In Vitro Diagnostic Medical Device Regulation (IVDR) in Europe, offers patients a dry swab collection method without requiring liquids or complex devices. The solution is designed to enable convenient mailing from home to laboratory facilities.

The self-collected samples require no manual preparation by lab technologists once received. When placed into the BD COR System, the samples undergo fully automated processing using robotics to prepare, analyze and report results.

"This certification marks a meaningful advancement in our efforts to expand access to cervical cancer screening around the world," said Nikos Pavlidis, worldwide president of BD Diagnostic Solutions, in a press release statement.

Key features of the system include onboard rehydration technology that eliminates manual sample preparation, 30-day dry sample stability, and a unified workflow for both clinician-taken and self-collected samples.

The technology uses the Copan FLOQSwab and maintains sample integrity through various temperature conditions, including up to five days at 45°C and four freeze/thaw cycles.

BD expects the solution to become commercially available across IVDR-recognized markets in the coming months. The company stated the technology aims to support public health efforts while improving laboratory efficiency.

The medical technology company, with more than 70,000 employees globally, develops innovative healthcare solutions across multiple sectors including diagnostics and research. With revenue growth of 7.86% and a market capitalization of $54.2 billion, BD continues to demonstrate strong market presence. According to InvestingPro analysis, the company appears undervalued based on its Fair Value calculations, with multiple growth indicators available in the Pro Research Report, which provides comprehensive analysis of BD among 1,400+ top US stocks.

In other recent news, Becton Dickinson reported preliminary fourth-quarter sales results that fell short of consensus estimates, though exact figures were not disclosed. The company also announced the upcoming departure of its Chief Financial Officer, Chris DelOrefice, who will leave on December 5 to pursue another opportunity. RBC Capital noted that the company’s preliminary revenue and earnings per share for the fiscal fourth quarter came in slightly below the low end of its previous guidance. Additionally, Becton Dickinson has launched the BD Incada Connected Care Platform, an AI-enabled cloud-based system designed to unify data from its medical devices. The platform is built on Amazon Web Services infrastructure and coincides with the release of the next-generation Pyxis Pro Automated Medication Dispensing Solution. In other developments, Becton Dickinson has enrolled the first patient in its XTRACT Registry study, which aims to evaluate the real-world performance of the Rotarex Catheter System for treating peripheral artery disease. The company also announced a collaboration with Opentrons Labworks to integrate robotic liquid-handling capabilities into its single-cell multiomics instruments, enhancing disease research and drug development processes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.